{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:53:37Z","timestamp":1793044417656,"version":"4.5.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.juro.2013.07.102","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T17:00:44Z","timestamp":1377190844000},"page":"20-27","source":"Crossref","is-referenced-by-count":109,"title":["Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition"],"prefix":"10.1097","volume":"191","author":[{"given":"Donald","family":"Lamm","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Arizona and BCG Oncology, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Persad","sequence":"additional","affiliation":[{"name":"Department of Urology\/Surgery, Bristol Royal Infirmary &amp; Bristol Urological Institute, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Brausi","sequence":"additional","affiliation":[{"name":"Department of Urology, AUSL Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[{"name":"Department of Urology, North York General Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[{"name":"Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[{"name":"Department of Urology, Fundaci\u00f3 Puigvert, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"B\u00f6hle","sequence":"additional","affiliation":[{"name":"Department of Urology, HELIOS Agnes Karll Hospital, Bad Schwartau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[{"name":"Department of Urology, Claude Bernard University, H\u00f4pital Edouard Herriot, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Soloway","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Miami School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2013.07.102_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-5347(17)45604-7","article-title":"Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder","volume":"135","author":"Herr","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","article-title":"Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer","volume":"143","author":"Mart\u00ednez-Pi\u00f1eiro","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.07.102_bib4","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","article-title":"A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer","volume":"156","author":"Pawinski","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib6","first-page":"1124","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.07.102_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib11","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2013.07.102_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"Shelley","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.07.102_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/cncr.25523","article-title":"Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial","volume":"117","author":"Stenzl","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2013.07.102_bib16","unstructured":"Merriam-Webster Online. Available at www.merriam-webster.com\/dictionary\/progression. Accessed October 10, 2012."},{"key":"10.1016\/j.juro.2013.07.102_bib17","unstructured":"MedlinePlus Medical Dictionary. Available at www.merriam-webster.com\/medlineplus\/progressive. Accessed October 10, 2012."},{"key":"10.1016\/j.juro.2013.07.102_bib18","unstructured":"Taber's Online: Taber's Medical Dictionary. Available at www.tabers.com\/tabersonline\/ub\/view\/Tabers\/143846\/47\/progression?q=Progression. Accessed October 10, 2012."},{"key":"10.1016\/j.juro.2013.07.102_bib19","unstructured":"National Cancer Institute at the National Institutes of Health: NCI Dictionary of Cancer Terms. Available at www.cancer.gov\/dictionary?cdrid=44078. Accessed October 10, 2012."},{"key":"10.1016\/j.juro.2013.07.102_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2013.07.102_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejso.2009.11.012","article-title":"Survival after cystectomy for invasive bladder cancer","volume":"36","author":"de Vries","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.juro.2013.07.102_bib22","series-title":"SEER Cancer Statistics Review, 1975-2007 (based on\u00a0November 2009 SEER data submission)","author":"Altekruse","year":"2010"},{"key":"10.1016\/j.juro.2013.07.102_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0022-5347(17)36924-0","article-title":"Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group","volume":"148","author":"Prout","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib24","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-5347(05)68075-5","article-title":"Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder","volume":"162","author":"Leblanc","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)67973-6","article-title":"Recurrence, progression and success in stage Ta grade\u00a03 bladder tumors treated with low dose bacillus Calmette-Gu\u00e9rin instillations","volume":"163","author":"Lebret","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib27","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"van der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.07.102_bib29","unstructured":"Amin MB, Reuter VE, Epstein JI et\u00a0al: Pathology consensus guidelines by the pathology of bladder cancer work group. In: Bladder Cancer. Edited by M Soloway and S Khoury. Paris: ICUD-EAU 2012; pp 63\u2013168."},{"key":"10.1016\/j.juro.2013.07.102_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.07.102_bib31","first-page":"31","article-title":"Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history","volume":"10","author":"Pasin","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urology.2010.01.032","article-title":"Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma","volume":"76","author":"Cao","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.juro.2013.07.102_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib35","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.juro.2013.07.102_bib36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib37","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.juro.2010.03.134","article-title":"Clinical outcome of primary versus secondary bladder carcinoma in situ","volume":"184","author":"Chade","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib38","unstructured":"Burger M, Witjes F, Babjuk M et\u00a0al: High-grade Ta, CIS and T1 urothelial carcinoma. In: Bladder Cancer. Edited by M Soloway and S Khoury. Paris: ICUD-EAU 2012; pp 247\u2013268."},{"key":"10.1016\/j.juro.2013.07.102_bib39","series-title":"Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)","author":"Babjuk","year":"2013"},{"key":"10.1016\/j.juro.2013.07.102_bib40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib41","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fern\u00e1ndez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1464-410X.2009.08694.x","article-title":"Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Gu\u00e9rin therapy and the decision for a repeat TUR","volume":"105","author":"Orsola","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2013.07.102_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Gu\u00e9rin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2013.07.102_bib45","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.eursup.2011.03.002","article-title":"Management of pT1G3 bladder cancer","volume":"10","author":"Thalmann","year":"2011","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.juro.2013.07.102_bib46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D","article-title":"Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2013.07.102_bib47","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.1999.17.10.3182","article-title":"Predicting cancer progression in patients with stage T1 bladder carcinoma","volume":"17","author":"Cheng","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2013.07.102_bib48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713051495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534713051495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2013.07.102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T03:34:40Z","timestamp":1651203280000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2013.07.102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1016\/j.juro.2013.07.102"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2013.07.102","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}